Assertio Holdings, Inc. withdrew earnings guidance for the year 2023. The company is withdrawing its 2023 financial outlook to assess the recent news of a generic indomethacin suppository approved by the United States Food and Drug Administration.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.96 USD | -8.57% | -6.80% | -10.28% |
05-06 | Assertio Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-06 | Transcript : Assertio Holdings, Inc., Q1 2024 Earnings Call, May 06, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.28% | 91.32M | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- ASRT Stock
- News Assertio Holdings, Inc.
- Assertio Holdings, Inc. Withdraws Earnings Guidance for the Year 2023